Lymphocyte activation by granulocyte macrophage‐colony stimulating factor in human bladder cancer

Toliou, T.; Stravoravdi, P.; Natsis, Konstantinos; Kirtsis, P.; Barich, A.; Konstantinos, Dimitriadis; Gigis, P.

doi:10.1046/j.1359-4117.2002.01008.x

Cited by 5 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the contrary, changes in G‐CSF or its receptor gene expression have not been found . Given the rarity of G‐/GM‐CSF‐secreting bladder tumors and an increasing use of recombinant G‐/GM‐CSF, appropriate diagnostic approaches are needed to identify patients to whom such therapies may be detrimental .…”

Section: Tumors Secreting G‐/gm‐csfmentioning

confidence: 99%

A role for G‐CSF and GM‐CSF in nonmyeloid cancers

Aliper¹,

et al. 2014

View full text Add to dashboard Cite

Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) modulate progression of certain solid tumors. The G-CSF- or GM-CSF-secreting cancers, albeit not very common are, however, among the most rapidly advancing ones due to a cytokine-mediated immune suppression and angiogenesis. Similarly, de novo angiogenesis and vasculogenesis may complicate adjuvant use of recombinant G-CSF or GM-CSF thus possibly contributing to a cancer relapse. Rapid diagnostic tools to differentiate G-CSF- or GM-CSF-secreting cancers are not well developed therefore hindering efforts to individualize treatments for these patients. Given an increasing utilization of adjuvant G-/GM-CSF in cancer therapy, we aimed to summarize recent studies exploring their roles in pathophysiology of solid tumors and to provide insights into some complexities of their therapeutic applications.

show abstract

Section: Tumors Secreting G‐/gm‐csfmentioning

confidence: 99%

A role for G‐CSF and GM‐CSF in nonmyeloid cancers

Aliper¹,

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Other studies also supported the safety and antitumor activity of intravesical rIFN-γ monotherapy (Stavropoulos et al, 2002). Studies also demonstrated that intravesical rGM-CSF was effective as a prophylactic therapy for patients with NMIBC after TURBT (Stravoravdi et al, 1999;Theano et al, 2002). In correlation with regression of marker lesions, intravesical rGM-CSF induced leukocyte migration and activation in the bladder mucosa.…”

Section: Combination Of Bcg With Th1 Cytokines For Bladder Cancer Trementioning

confidence: 73%

Th1 Cytokine-Secreting Recombinant Bacillus Calmette-Guérin: Prospective Use in Immunotherapy of Bladder Cancer

Luo¹,

Henning²,

O’Donnell³

2011

Current Cancer Treatment - Novel Beyond Conventional Approaches

View full text Add to dashboard Cite

“…Other studies also supported the safety and antitumor activity of intravesical rIFN- γ monotherapy [72]. Studies also demonstrated that intravesical rGM-CSF was effective as a prophylactic therapy for patients with NMIBC after TURBT [73, 74]. In correlation with regression of marker lesions, intravesical rGM-CSF induced leukocyte migration and activation in the bladder mucosa.…”

Section: Combination Of Bcg With Th1 Cytokines For Bladder Cancer mentioning

confidence: 88%

Th1 Cytokine-Secreting RecombinantMycobacterium bovisBacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer

Luo

Henning

O’Donnell

2011

Clinical and Developmental Immunology

View full text Add to dashboard Cite

Intravesical instillation of Mycobacterium bovis bacillus Calmette-Guérin (BCG) has been used for treating bladder cancer for 3 decades. However, BCG therapy is ineffective in approximately 30–40% of cases. Since evidence supports the T helper type 1 (Th1) response to be essential in BCG-induced tumor destruction, studies have focused on enhancing BCG induction of Th1 immune responses. Although BCG in combination with Th1 cytokines (e.g., interferon-α) has demonstrated improved efficacy, combination therapy requires multiple applications and a large quantity of cytokines. On the other hand, genetic manipulation of BCG to secrete Th1 cytokines continues to be pursued with considerable interest. To date, a number of recombinant BCG (rBCG) strains capable of secreting functional Th1 cytokines have been developed and demonstrated to be superior to BCG. This paper discusses current rBCG research, concerns, and future directions with an intention to inspire the development of this very promising immunotherapeutic modality for bladder cancer.

show abstract

Lymphocyte activation by granulocyte macrophage‐colony stimulating factor in human bladder cancer

Abstract: The present study led us to speculate on the use of GM-CSF as a new alternative approach in the management of TCC through immunomodulation.

Cited by 5 publications

References 6 publications

A role for G‐CSF and GM‐CSF in nonmyeloid cancers

A role for G‐CSF and GM‐CSF in nonmyeloid cancers

Th1 Cytokine-Secreting Recombinant Bacillus Calmette-Guérin: Prospective Use in Immunotherapy of Bladder Cancer

Th1 Cytokine-Secreting RecombinantMycobacterium bovisBacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer

Contact Info

Product

Resources

About